PreciseDx, a cancer risk stratification company that provides patient-specific risk information through analysis of morphology features, raised $10.8 million in Series A funding, per Fortune’s Term Sheet. Merck Global Health Innovation Fund led the round and was joined by investors including the Mount Sinai Health System, Agilent Technologies, IBM Ventures, and the Hobart Group.
Related Posts
Monogram Health Closes $375M Growth Capital Raise
Funding participants included CVS Health, Cigna Ventures, Humana, Memorial Hermann Health System, and SCAN, as well as from both new and existing investors.
January 19, 2023
Stanford Spinout Raises $14M for its Point-of-Care Physician Consult Service
Atropos Health provides physicians with real-world evidence at the point of care to help them make more informed decisions when treating their patients.
August 10, 2022
TPG to Acquire Leading Specialty Healthcare IT Platform Nextech for $1.4B
TPG is investing in Nextech through TPG Capital, its U.S. and European late-stage private equity platform.
August 9, 2023